Researchers have determined that many potentially adverse effects are not present on fact-based health care reviews.
Perspective on the potential effects of pricing of biosimilars compared with biologics as other biosimilars enter the market.
The economics of one and done gene therapies dictate a revenue model that requires outcomes-based risk.